Navigation Links
Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
Date:3/30/2009

LA JOLLA, Calif., March 30 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that the United States District Court of the Southern District of New York dismissed proceedings filed in February 2005 by former stockholders of Axonyx Inc. ("Axonyx") against Axonyx and several of Axonyx's former directors and officers. TorreyPines acquired Axonyx Inc. in 2006. The plaintiffs alleged that the defendants made misleading statements related to Phase III clinical trials of Axonyx's drug candidate, phenserine. The complaint was dismissed in its entirety. In January 2009 a related outstanding derivative action against Axonyx was discontinued by the New York Supreme Court.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, and xerostomia. The company currently has three clinical stage product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at www.tptxinc.com.

This press release contains forward-looking statements or predictions. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2008 and TorreyPines other SEC reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and TorreyPines undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

    Company contact:                                Investor contact:
    Paul Schneider                                  Rhonda Chiger
    TorreyPines Therapeutics, Inc.                  Rx Communications Group
    858-623-5665 x 125                              (917) 322-2569
    pschneider@TPTXinc.com                          rchiger@rxir.com


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ev3 and FoxHollow Announce Date for Special Meeting of FoxHollow Stockholders to Vote on Proposed Merger
2. Micrus Endovascular to Webcast Fiscal 2007 Annual Meeting of Stockholders
3. Kyphon Stockholders Approve Merger with Medtronic
4. Paramount Stockholders Approve Acquisition of Chem Rx
5. Nabi Biopharmaceuticals Stockholders Approve Asset Sale
6. Halozyme Therapeutics Amends Stockholder Rights Plan
7. Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting
8. VaxGen Addresses MPM Claims in Letter to Stockholders
9. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
10. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
11. Special Stockholders Meeting to Elect Directors Set for March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 2016 , ... Amendia, Inc., a leading designer, developer, manufacturer ... completion of a significant transaction and partnership that positions Amendia for accelerated growth ... Kohlberg & Company, L.L.C. (“Kohlberg”), a leading private equity firm specializing in middle ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... fundamentals to transform technology into a viable company, CereScan’s CEO, John Kelley, joined ... Kelley, a recognized leader and mentor in the Denver area business community, shared ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Intelligent Implant ... by the FDA via 510(k) for sale in the United States. These components ... posterior thoraco-lumbar fusions. With one-level sales beginning in October of 2015, the company ...
(Date:4/28/2016)... April 28, 2016 The report ... Brayton Cryocoolers), Service (Technical Support, Product Repairs & Refurbishment, ... Global Forecast to 2022", published by MarketsandMarkets, the global ... by 2022, at a CAGR of 7.29% between 2016 ... Tables and 94 Figures spread through 159 Pages and ...
Breaking Biology Technology:
(Date:3/17/2016)... 2016 ABI Research, the leader in ... biometrics market will reach more than $30 billion ... 2015. Consumer electronics, particularly smartphones, continue to boost ... to reach two billion shipments by 2021 at ... , Research Analyst at ABI Research. "Surveillance is ...
(Date:3/14/2016)... NXTD ) ("NXT-ID" or the "Company"), a company ... of a new series of commercials on Time Warner Cable ... .  The commercials will air on Bloomberg TV, Fox Business ... show. --> NXTD ) ("NXT-ID" or the "Company"), ... the airing of a new series of commercials on Time ...
(Date:3/11/2016)... , March 11, 2016 ... market research report "Image Recognition Market by Technology (Pattern ... and Advertising), by Deployment Type (On-Premises and Cloud), by ... 2022", published by MarketsandMarkets, the global market is expected ... USD 29.98 Billion by 2020, at a CAGR of ...
Breaking Biology News(10 mins):